Objective: To develop a more age-appropriate spirometric definition of chronic obstructive pulmonary disease (COPD) among older persons. Methods: Using data from the Third National Health and Nutrition Examination Survey (NHANES III), we developed a two-part spirometric definition of COPD in older persons, aged 65e80 years, that 1) determines a cut-point for the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV 1 /FVC) based on mortality risk; and 2) among persons below this critical FEV 1 /FVC threshold, determines cut-points for the FEV 1 , expressed as a standardized residual percentile (SR-tile) and based on the prevalence of respiratory symptoms and mortality risk. Measurements included spirometry, health questionnaires, and mortality (National Death Index). Results: There were 2480 older participants with a mean age of 71.7 years; 1372 (55.4%) had a smoking history, 1097 (44.2%) had respiratory symptoms and, over the course of 12-years, 868 (35.0%) had died. Among participants with an FEV 1 /FVC < .70 and FEV 1 < 5th SR-tile, representing 7.7% of the cohort, the risk of death was doubled (adjusted hazard ratio, 2.01; 95% confidence interval [CI], 1.60e2.54). Among participants with an FEV 1 /FVC < .70 and FEV 1 < 10th SRtile, representing 13.4% of the cohort, the prevalence of respiratory symptoms was elevated (adjusted odds ratio, 2.44; CI, 1.79e3.33). Conclusion: In a large, nationally representative sample of community-living older persons, defining COPD based on an FEV 1 /FVC < .70, with FEV 1 cut-points at the 10th and 5th SR-tiles, identifies individuals with an increased prevalence of respiratory symptoms and an increased risk of death, respectively. Published by Elsevier Ltd. 
Introduction
Chronic obstructive pulmonary disease (COPD), a leading cause of disability and death worldwide, is defined by chronic airflow limitation that is not fully reversible. 1e9 The airflow limitation is established spirometrically, based solely on a reduced ratio of forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity (FVC), with severity subsequently categorized according to the FEV 1 .
2e9 This strategy for defining COPD has a physiological basis because airflow limitation increases the risk of death and usually precedes the onset of dyspnea or exercise intolerance. 10, 11 In contrast, defining COPD on the basis of disease criteria alone (e.g. chronic bronchitis) lacks diagnostic accuracy, because cough and sputum production may occur in the absence of airflow limitation and are not independent predictors of death. Current spirometric guidelines are potentially problematic, however, for at least three reasons. First, the threshold that establishes a reduced FEV 1 /FVC remains controversial. 6e8 For example, the Global Initiative for Obstructive Lung Disease (GOLD) and the American College of Physicians (ACP) advocate an FEV 1 /FVC threshold based on a fixed-ratio, 4, 13 but this by itself cannot distinguish clinicallysignificant pathology from normal age-related increases in airflow limitation. 7 Alternatively, the American Thoracic Society (ATS) and the European Respiratory Society (ERS) advocate an FEV 1 /FVC threshold based on the lower limit of normal (LLN), 9 but this is derived from regression equations that have limited explanatory ability when applied to an elderly population (i.e., R 2 range of .03e.08). 8, 14, 15 Second, the present method of reporting the FEV 1 as percent predicted (%Pred) is fundamentally flawed, because it does not account for differences in the variability of the reference group across the lifespan. 16, 17 As a result, a given FEV 1 %Pred value is not equivalent for all persons regardless of age, height, sex, and ethnicity. 16, 17 Third, current spirometric guidelines, in general, lack clinical validation regarding important measures such as mortality and respiratory symptoms. 4, 9, 13 These problems with current spirometric guidelines are most evident among older persons. Specifically, conventional cut-points for the FEV 1 /FVC ratio yield prevalence rates for COPD (in the U.S.) that range widely from 16% to 42%, with most affected individuals subsequently categorized by the FEV 1 %Pred as having ''mild'' COPD. 6, 7 Hence, current spirometric guidelines may lead to misclassification (mainly over-diagnosis) of COPD among older persons and, in turn, potentially compromise patient care. 7, 13, 18 As an alternative spirometric strategy, we propose that COPD be defined by a two-step process that 1) determines a cut-point for the FEV 1 /FVC based on mortality risk; and 2) among persons below this critical FEV 1 /FVC threshold, determines cut-points for the FEV 1 , expressed as a standardized residual percentile (SR-tile) and based on the prevalence of respiratory symptoms and mortality risk. An SR-tile is simply a Z-score that has been converted to a percentile, 16, 17 and is analogous to what is currently reported for bone mineral density testing. 19 Importantly, the SR-tile method accounts for variability in age, height, sex, and ethnicity. 16, 17 In the present study, we have applied our strategy for defining COPD in a large nationally representative sample of community-living older persons, which included a large proportion of women and minorities, and discuss how this approach is more clinically meaningful than those provided in published guidelines. 4, 9, 13 
Methods

Study population
We used data from the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative sample of Americans assembled in 1988e1994, with mortality surveillance through December 31, 2000. 20, 21 Our source population included 2480 community-living NHANES III participants, aged 65e80 years, who were white, AfricanAmerican, or Mexican-American, had no self-reported asthma, and had completed a health questionnaire, a brief cognitive assessment, and at least two ATS acceptable spirometric maneuvers. 22 As per current ATS recommendations, we did not exclude participants based on spirometric reproducibility criteria. 3 
Clinical measures
As described elsewhere, 20 NHANES III recorded the presence of respiratory symptoms in the prior 12 months, including chronic cough or sputum production lasting 3 or more consecutive months, dyspnea on exertion, and wheezing or ''whistling in the chest''. Other clinical data included chronic conditions, including self-reported, physician-diagnosed COPD and asthma, as well as smoking history, self-reported health status, body mass index (BMI), and cognitive function. Memory impairment was defined as a score less than 2 on delayed recall of a 3-item word list or a score less than 4 on delayed recall from a 6-item story.
Spirometry
NHANES III utilized a customized Ohio Sensormed 827 dry rolling seal spirometer. 20 After calibration, each participant performed 5e8 FVC maneuvers, with the goal of meeting ATS criteria. 20, 22 As shown in the appendix, and following current guidelines, 9 we determined regression equations in an NHANES III reference group of age-matched never-smokers, with no chronic conditions and no respiratory symptoms. Also as per guidelines, 9 we used age and height as predictor variables for FEV 1 and FVC within each sex and ethnic group. Our subsequent procedures, however, differed from those of prior studies that calculated the FEV 1 as %Pred (i.e., measured/ predicted Â 100). 4, 5, 6, 8 Instead, in a reference group of agematched, healthy never-smokers, we calculated the constant that quantified the spread of the reference data, namely the standard deviation of the residuals. (A ''residual'' is the difference between a measured and predicted value.) Based on the regression equations and the spread of the reference data, we then expressed the measured FEV 1 of each participant as a standardized residual (SR), calculated as [(measured À predicted)/(standard deviation of the residuals)]; a percentile based on the SR was subsequently computed (SRtile). 16, 17 To illustrate, an SR of À1.64 corresponds to the 5th percentile, an SR of 0 corresponds to the 50th percentile, and an SR of 1.64 corresponds to the 95th percentile. 16, 17 By standardizing the residuals to the spread of the reference data, the SR method accounts for variability due to age, sex, height, and ethnicity and reports FEV 1 SR-tile values on an easy-to-interpret scale of 0e100, whereas %Pred does not. 16, 17 We next classified participants based on their SR-tile values for FEV 1 , using cut-points established for the FEV 1 %Pred (80, 50, and 30) by the Global Initiative for Obstructive Lung Disease (GOLD). 4 We modified these cut-points to 50, 30, 10, and 5 SR-tiles because only a small number of NHANES III participants with FEV 1 /FVC values below the critical threshold, as defined below, had an FEV 1 > 80th SR-tile (n Z 21) whereas a large number had an FEV 1 < 30th SR-tile (n Z 321).
Lastly, we calculated the LLN for the FVC, to help define the referent group for our mortality risk analysis, i.e., the FVC criterion was used to exclude persons with restrictive lung disease. 8 We do not report the LLN for the FEV 1 /FVC because predicted values could not be determined reliably. In contrast to the FEV 1 and FVC, regression equations for the FEV 1 /FVC had very low R 2 values, ranging from 0.01 to 0.07, with only one exception (the value for Mexican-females was 0.15). This lack of explanatory capacity persisted when we analyzed the ratio of the FEV 1 to the forced expiratory volume in 6 s (FEV6), which yielded R 2 values of 0.01e0.08. These results are similar to those published in other cohorts of older persons.
14,15
Primary outcome
Our primary outcome was all-cause mortality, ascertained from a public-use linked mortality file that contains information based on the National Death Index, with follow-up through December 31, 2000. 21 Vital status was available on all but one participant. 21 Statistical analysis SUDAAN version 9.0.1 (Research Triangle Park) was used to estimate hazard ratios (Cox proportional hazards analysis) and odds ratios (logistic regression), with a p-value < 0.05 (two-sided) denoting statistical significance. 23 Proportional hazard assumptions for survival models were tested using interaction terms crossing the time-to-event outcome with each variable in the multivariable model. If significant at the 0.05 level, these interaction terms were retained in the final model. The incidence rate and 95% confidence interval (CI) for death were expressed in personeyears. Participants who had not died were censored at the end of the follow-up period.
As a first step, we varied the cut-point for the FEV 1 /FVC in 0.05 decrements below a ratio of 0.80, and fit separate Cox regression models for all-cause mortality, each adjusted for age, height, sex, ethnicity, smoking history, BMI, chronic conditions, self-reported health status, and cognition. Higher order effects were tested for the continuous covariates and were included in the final models if they met the forward selection criterion of p < 0.20. 24 The first FEV 1 /FVC cut-point below 0.80 that yielded a statistically significant increase in the risk of death was termed the ''critical'' threshold.
Next, among participants with an FEV 1 /FVC below the critical threshold, we evaluated time-to-death using the KaplaneMeier method with strata defined according to FEV 1 cut-points, expressed as SR-tile. We then determined the independent association between the FEV 1 SR-tile cut-points and death using Cox proportional hazards, adjusted for the same covariates as described earlier. The FEV 1 SR-tile cutpoints were treated as nominal categories, with the referent group including participants with normal pulmonary function, defined by an FEV 1 /FVC ! critical threshold and an FVC ! LLN. Similarly, we also evaluated the associations between FEV 1 SRtile cut-points and the presence of respiratory symptoms, by calculating odds ratios using logistic regression.
To enhance the interpretation of our findings, we evaluated the prevalence of smoking exposure and reduced health status according to the FEV 1 SR-tile cut-points among participants with an FEV 1 /FVC below the critical threshold, and we calculated the FEV 1 %Pred values that corresponded to these SR-tile cut-points. d Defined by a score of 0e1 on delayed recall of a 3-item word list or a score of 0e3 on delayed recall from a 6-item story.
Results
As shown in Table 1 , our study population had a mean age of approximately 72 years, with a majority being current or former smokers. The five most common self-reported chronic conditions were hypertension, arthritis, diabetes mellitus, myocardial infarction, and chronic obstructive pulmonary disease. About a third of the participants had fair-to-poor health status and memory impairment, respectively, and 44.4% endorsed respiratory symptoms. Over the 12-year follow-up period, 868 (35.0%) participants died, yielding a mortality rate of 4.6 per 100 personeyears (95% confidence interval [CI] 4.3, 4.9). Table 2 provides adjusted hazard ratios for all-cause mortality according to the FEV 1 /FVC. An increased mortality risk was first observed at a cut-point below .70, with an adjusted hazard ratio of 1.23 (95%CI, 1.03e1.47). Fig. 1 displays KaplaneMeier survival curves among participants with an FEV 1 /FVC < .70, stratified by FEV 1 SR-tile. Survival was notably lower for participants with an FEV 1 < 5th SR-tile. As shown in Table 3 , a threshold effect for mortality was observed at an FEV 1 < 5th SR-tile, with an adjusted hazard ratio of 2.01 (95%CI, 1.60e2.54), representing 7.7% of the cohort. Table 4 reports adjusted odds ratios for respiratory symptoms, based on FEV 1 SR-tile among participants with an FEV 1 /FVC < .70 versus those with normal pulmonary function. A graded relationship was observed, with FEV 1 stages at <5th SR-tile and 5the9th SR-tiles, respectively, demonstrating statistically significant elevations in the odds ratio. When these two stages were combined, i.e., FEV 1 < 10th SRtile, the adjusted odds ratio for respiratory symptoms was 2.44 (95%CI, 1.79e3.33), representing 13.4% of the cohort. 3 , memory impairment, self-reported health status by time interaction, and chronic conditions. The referent group for each FEV 1 /FVC cut-point is the population above the specified cut-point. Table 5 provides the mean values for the FEV 1 /FVC and the prevalence of ever-smokers and reduced health status according to FEV 1 SR-tile stages among participants with an FEV 1 /FVC < .70. Graded relationships were observed, with an FEV 1 < 5th SR-tile having the lowest mean value for the FEV 1 /FVC and the highest prevalence of ever-smokers and reduced health status, respectively. Table 6 provides the FEV 1 %Pred values that corresponded to the 10th and 5th SR-tiles, respectively, for a person of average height. For each of these SR-tile cut-points, the %Pred values varied considerably based on age, ethnicity, and sex. For example, a 65-year old male of average height had an FEV 1 value at the 5th SR-tile that ranged from 51%Pred in African-Americans to 69%Pred in white Americans.
Years of Follow-Up
Discussion
In a large, nationally representative sample of communityliving persons aged 65e80 years, we found that a two-part spirometric definition of COPD that includes an FEV 1 / FVC < .70, with FEV 1 cut-points at the 10th and 5th SR-tiles, identifies individuals with an increased prevalence of respiratory symptoms and an increased risk of death, respectively. Our strategy for defining COPD has a strong clinical and physiological basis. First, we have established spirometric cut-points that are associated with important clinical measures. 25 All-cause mortality is considered the most definitive health outcome, and was the primary endpoint in landmark studies of oxygen therapy in COPD. 25 In addition, respiratory symptoms are the most common and distressing feature of COPD. 25 Second, we have evaluated the FEV 1 as an SR-tile rather than %Pred. 4, 9, 13 Because it does not consider the spread of the reference data, reporting the FEV 1 as %Pred incorrectly assumes that a given value is equivalent for persons of different age, height, sex, and ethnicity. 16, 17 The SR-tile method yields, however, a value that is applicable to all persons because it considers the spread of the reference data. 16, 17 To illustrate, for an NHANES III participant of average height, we found that FEV 1 values at the 5th SR-tile varied from 51%Pred to 77%Pred, depending on the ethnicity, sex, and age of the individual; see Table 6 . In contrast to our proposed strategy, current guidelines for COPD recommend spirometric cut-points that have not been clinically validated among older persons, and report the FEV 1 as %Pred. 4, 9, 13 Our results also help to clarify the best approach for establishing a critical threshold for the FEV 1 /FVC ratio, as part of a spirometric definition of COPD. We found that a fixed-ratio at a threshold of .70 is associated with an increased risk of death, which is consistent with GOLD guidelines. 4 Among persons with an FEV 1 /FVC ratio below this critical threshold, we established COPDdin contrast to GOLD and other spirometric guidelines 4, 9, 13 don the basis of FEV 1 SR-tile cut-points that were defined by mortality risk and the prevalence of respiratory symptoms. Using this strategy, 7.7% of our study population had a severe form of COPD, defined by an FEV 1 /FVC < .70 and an FEV 1 < 5th SRtile, which conferred an increased risk of death and an increased prevalence of respiratory symptoms. This subgroup also had the highest prevalence of smoking exposure and reduced health status, and the lowest mean value for the FEV 1 /FVC. Participants with an FEV 1 / FVC < .70 and an FEV 1 at the 5the9th SR-tiles, representing 5.7% of the study population, had a milder form of COPD, which conferred an increased prevalence of respiratory symptoms but not an increased risk of death. This subgroup had the second highest prevalence of smoking exposure and reduced health status, and the second lowest mean value for the FEV 1 /FVC.
Because neither the risk of death nor prevalence of respiratory symptoms was elevated, we would argue that participants with an FEV 1 /FVC < .70 but an FEV 1 ! 10th SRtile have airflow limitation, but not COPD. Although longitudinal studies are needed, this latter group may be heterogeneous, including persons who simply have normal age-related increases in airflow limitation and those who will experience declines in pulmonary function over time (i.e., transition to COPD). 26 As compared with current guidelines, 4,9,13 our two-part spirometric definition posits that a reduced FEV 1 /FVC, although necessary for defining airflow limitation, is insufficient to establish a diagnosis of COPD. Developmentally, after achieving peak pulmonary function at about 20 years of age, airflow limitation increases with age, 27 principally due to increasing rigidity of the chest wall and decreasing elastic recoil of the lung. 35 Although COPD is also characterized by airflow limitation, this effect is due to small airways' disease and parenchymal destruction. 4, 36 Consequently, a reduced FEV 1 /FVC as a measure of airflow limitation can be caused by normal aging and/or clinicallysignificant pathology. 7, 8 To make this distinction, it is necessary to consider the FEV 1 because it is associated with COPD-related airway inflammation in persons with established airflow limitation. 36 Consequently, among older persons, our spirometric strategy likely reduces potential misclassification of COPD, as evidenced by an overall prevalence (13.4%) that is more clinically realistic than that generated by GOLD guidelines (34.5%).
If routinely implemented, our spirometric strategy for defining COPD could lead to improvements in patient care. For example, with GOLD guidelines, exercise intolerance in an older patient who has coexisting cardiopulmonary risk factors, anemia, and a history of physical inactivity might be attributed primarily to COPD instead of to one or more of the patient's comorbid conditions. Because cut-points are based on clinical measures relevant to COPD, our spirometric strategy could lead to a more targeted use of COPD-specific pharmacotherapy and, as a result, reduce the frequency of medication-related adverse events. 18 We recognize potential limitations to our study. First, a threshold based on the LLN for the FEV 1 /FVC could not be reliably determined. Unlike the FEV 1 and FVC, regression equations for the FEV 1 /FVC lack explanatory ability in older persons. This may be attributable to age-related increases in lung function variability, leading to normal values for the FEV 1 /FVC that range widely and are significantly skewed e in comparison to the FEV 1 and FVC alone. 27 Moreover, because prior work has shown that elderly persons with an FEV 1 /FVC < .70 but >LLN have an increased risk of death, 8 the clinical validity of the LLN is uncertain. Our inability to calculate the LLN of the FEV 1 /FVC likely had little effect on our estimate of COPD prevalence, since our strategy relies ultimately on the FEV 1 SR-tile to establish a diagnosis.
Second, the cut-points that we identified for the FEV 1 /FVC and FEV 1 SR-tile were based on a single cohort of older persons. Further validation of these cut-points, with an expanded array of clinically relevant outcomes (including health care utilization), will be required in other cohorts of older persons, as well as in other age groups.
Third, evaluating an outcome based on all-cause mortality rather than COPD-specific mortality might be considered a limitation. Prior work has shown, however, that COPD is commonly underreported as a cause of death, even among patients with symptomatic COPD. 28 Furthermore, COPD increases the risk of death from cardiovascular disease and lung cancer, and the number of deaths from these causes is much greater than those from respiratory disease among patients with COPD. 28e30 Fourth, our spirometric definition of mild COPD is based on the presence of respiratory symptoms, which are not necessarily specific to COPD. 37 Nonetheless, respiratory symptoms are the most distressing feature of COPD and can lead to disability and increased healthcare utilization. 25, 37 In addition, the graded relationship observed for the presence of respiratory symptoms across the FEV 1 SR-tile stages (Table 4 ) enhances the validity of our spirometric definition of COPD.
Finally, because spirometry in NHANES III was not obtained after a bronchodilator, we could not assess reversibility, a recommended criterion for defining COPD. 4 It is unlikely, however, that the absence of information on ''reversibility'' had a meaningful effect on our results, because 1) persons with self-reported asthma were excluded, 2) prior work has shown that only 3% of abnormal prebronchodilator FEV 1 /FVC ratios normalize in response to a bronchodilator, 31,32 and 3) bronchodilator reversibility, as defined by the FEV 1 response, is neither a sufficient criterion to exclude COPD nor an independent predictor of mortality. 33, 34 Nevertheless, we acknowledge that our spirometric analyses may have included a small number of participants with asthma, either as a sole form of obstructive airways disease or comorbidity.
In conclusion, among older persons, we are proposing a revised spirometric definition of COPD that identifies individuals with an increased prevalence of respiratory symptoms and an increased risk of death. If confirmed in other populations of older persons, this definition of COPD could lead to improvements in patient care.
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Appendix Multiple regression models for spirometric measures in ''healthy'' NHANES III participants aged 65e80 years. Abbreviations: NHANES III Z The third national health and nutrition examination survey; FEV 1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity; Intercept PRD Z predicted intercept; Intercept LLN Z lower limit of normal for the intercept (i.e., intercept PRD À [1.645 Â standard error of the intercept PRD ]); Age Z years; height Z cm; RSD Z standard deviation of the residual; R 2 Z the explained variation; e Z represent effects that were not statistically significant at the .05 level (all other listed effects were significant at p < .05).
a ''Healthy'' included never-smokers, with no chronic conditions and no respiratory symptoms. b To enhance interpretability, the predictor variables of age and height were centered, i.e., for each participant the mean spirometric value was subtracted from the measured value.
